Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy

Lasers in Medical Science
Gustavo Henrique RodriguesVladmir Claudio Cordeiro Lima

Abstract

The present study outlines the clinical impact and risk factors of oral mucositis in 79 patients with multiple myeloma following high-dose melphalan for autologous transplant. All patients underwent daily prophylactic low-level indium gallium aluminum phosphate diode laser therapy (660 nm, 15 mW, 3.75 J/cm(2), 10 s per point) from the beginning of the conditioning regimen up to day +2. Oral mucositis assessments were made daily until hospital discharge. For analysis, oral mucositis was divided into two groups according to severity: group 1, patients with oral mucositis grade <III (n = 71) and group 2, patients with oral mucositis grade ≥III (n = 8). Univariate logistic models were used to determine the risk factors. Patients in group 1 were found to have statistically fewer days of oral pain than those in group 2 (3.94 and 6.25 days, respectively, p = 0.014). Morphine was required in 75% of patients in group 2, versus 42.25% in group 1 (p = 0.06). Risk of severe oral mucositis was associated with higher serum creatinine levels (OR = 6.10; 95% CI 1.25-31.60; p = 0.02) and older age (OR = 1.21; 95% CI 1.05-1.47; p = 0.027). Severe oral mucositis was associated with worse clinical outcomes. Older patients and those with renal dysf...Continue Reading

References

Jul 11, 1998·Oral Oncology·W ParulekarR C Jordan
Feb 29, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·H GoldschmidtA D Ho
Sep 21, 2001·British Journal of Haematology·A BadrosG Tricot
Jun 21, 2002·The Cancer Journal·Siu-Fun Wong, Petra Wilder-Smith
Apr 27, 2004·Cancer·Stephen T SonisUNKNOWN International Society for Oral Oncology
Dec 17, 2004·The New England Journal of Medicine·Ricardo SpielbergerChristos Emmanouilides
Jun 11, 2005·European Journal of Haematology·Lene M KnudsenChristian Geisler
Mar 30, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mark M SchubertMohd Hamdi
Feb 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole BlijlevensUNKNOWN European Blood and Marrow Transplantation Mucositis Advisory Group
Feb 24, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Nilza Nelly Fontana LopesMaria Teresa Seixas Alves
May 29, 2009·Photomedicine and Laser Surgery·Chukuka S Enwemeka
Jun 19, 2009·The New England Journal of Medicine·Jean-Luc Harousseau, Philippe Moreau
Jun 23, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gaurav C ParikhMuzaffar H Qazilbash
Jun 23, 2009·Lancet·Marc S RaabKenneth C Anderson
Oct 26, 2010·Photomedicine and Laser Surgery·Geisa Badauy Lauria SilvaMaria Alves Garcia Silva
Sep 25, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Cesar MiglioratiUNKNOWN Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (
Mar 13, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ajay K NookaEdmund K Waller

❮ Previous
Next ❯

Citations

Oct 7, 2017·Current Opinion in Supportive and Palliative Care·Joanne M Bowen, Hannah R Wardill
Jul 10, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yehuda ZadikUNKNOWN Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (
Apr 14, 2021·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Marina CurraManoela Domingues Martins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.